Biogen will open a West Coast hub in South San Francisco after acquiring a Peninsula drugmaker. HI-Bio's operations have expanded since the acquisition, doubling employees to 100 and planning to ...

Visit a quote page and your recently viewed tickers will be displayed here. Mr. Hawkins is the retired Chairman and CEO of Medtronic and has had a long and distinguished career in the Medical Devices ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results , with sales up 6.1% year on year to $2.43 billion. Its ...

Biogen (NASDAQ:BIIB) lowered its full-year outlook to reflect the impact of a $165 million upfront transaction payment to ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.

The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ:BIIB) develops and markets therapies for neurological conditions, including multiple ...